BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9014288)

  • 1. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer.
    Boursnell ME; Rutherford E; Hickling JK; Rollinson EA; Munro AJ; Rolley N; McLean CS; Borysiewicz LK; Vousden K; Inglis SC
    Vaccine; 1996 Nov; 14(16):1485-94. PubMed ID: 9014288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
    Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
    Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector.
    Gao L; Chain B; Sinclair C; Crawford L; Zhou J; Morris J; Zhu X; Stauss H
    J Gen Virol; 1994 Jan; 75 ( Pt 1)():157-64. PubMed ID: 7509369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18.
    Zhao L; Liu B; Ren J; Feng J; Pang Z; Gao J; Zhang H; Tan W; Tian H; Ruan L
    Virol J; 2011 Jun; 8():302. PubMed ID: 21672263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].
    Huang W; Tian HW; Ren J; Fan JT; Zhao L; Bian T; Lu ZH; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):240-3. PubMed ID: 16261206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.
    Borysiewicz LK; Fiander A; Nimako M; Man S; Wilkinson GW; Westmoreland D; Evans AS; Adams M; Stacey SN; Boursnell ME; Rutherford E; Hickling JK; Inglis SC
    Lancet; 1996 Jun; 347(9014):1523-7. PubMed ID: 8684105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
    Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
    Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
    Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
    J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
    Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Construction of recombinant vaccinia virus co-expressing mutant E6 plus E7 proteins and detection of its immunogenicity and antitumor response].
    Zhi H; Han L; Ren J; Tian H; Luo W; Liang Y; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Dec; 16(4):341-4. PubMed ID: 12665900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental study of the immuno-protective activity of recombinant vaccinia virus expressing HPV58 E7].
    Luo LQ; Li J; Liu X; Zhang YH
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Feb; 25(1):43-6. PubMed ID: 12905606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
    Daemen T; Regts J; Holtrop M; Wilschut J
    Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The induction of cytotoxic T-lymphocyte precursor cells by recombinant vaccinia virus expressing human papillomavirus type 16 L1.
    Zhou JA; McIndoe A; Davies H; Sun XY; Crawford L
    Virology; 1991 Mar; 181(1):203-10. PubMed ID: 1847256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The recombinant vaccinia viruses expressing HPV type 16 wild or mutant E7 protein elicit immunity against tumor cells in mice].
    Zhi H; Han L; Ren J; Tian HW; Lao WF; Liang Y; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Sep; 15(3):222-5. PubMed ID: 11986689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-replicating recombinant vaccinia virus expressing HPV16 E6 and E7 proteins elicits anti-tumor immunity in mice].
    Luo WF; Han LQ; Ren J; Tian HW; Lu ZH; Zhao L; Gu SY; Ruan L
    Zhonghua Zhong Liu Za Zhi; 2003 Jul; 25(4):335-9. PubMed ID: 12921560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Construction of recombinant vaccina virus of HPV16 and its antitumor effect].
    Huang W; Tian HW; Ren J; Fan JT; Zhao L; Ruan L
    Ai Zheng; 2005 Jul; 24(7):817-22. PubMed ID: 16004807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
    Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
    Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
    Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
    J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.